Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of STI-1558 in Healthy Chinese Subjects
NCT06044233Phase 1Completed
- Sponsor
- ACEA Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Oct 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olgotrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ACEA Pharmaceuticals. Primary endpoints: Maximum Observed Concentration up to 2 weeks, Area Under the Curve from time 0 to last time point up to 2 weeks and 1 more. Started Sep 2023; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06044233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044233.